85. Idiopathic interstitial pneumonia
514 clinical trials, 377 drugs (DrugBank: 108 drugs), 97 drug target genes, 204 drug target pathways
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-001261-17-IE (EUCTR) | 28/01/2005 | 08/12/2004 | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Trade Name: Immukin Product Name: Interferon gamma-1b | InterMune | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Ireland | |||
| 2 | EUCTR2004-000029-31-IE (EUCTR) | 28/01/2005 | 08/12/2004 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE | Idiopathic Pulmonary Fibrosis (IPF) | Trade Name: Immukin Product Name: Interferon gamma-1b | InterMune | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Ireland | ||
| 3 | NCT00075998 (ClinicalTrials.gov) | December 2003 | 12/1/2004 | The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial) | Idiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary Fibrosis | Drug: Interferon gamma-1b (Actimmune) | InterMune | NULL | Terminated | 40 Years | 79 Years | Both | 826 | Phase 3 | United States |
| 4 | NCT00076635 (ClinicalTrials.gov) | November 2003 | 28/1/2004 | An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Lung Disease | Drug: Interferon gamma-1b | InterMune | NULL | Terminated | N/A | N/A | Both | 91 | Phase 3 | United States |
| 5 | NCT00052052 (ClinicalTrials.gov) | September 2002 | 21/1/2003 | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis. | Lung Disease;Pulmonary Fibrosis | Drug: interferon-gamma 1b | InterMune | NULL | Completed | 20 Years | 79 Years | Both | 210 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00052039 (ClinicalTrials.gov) | April 2002 | 21/1/2003 | A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone | A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone | Lung Disease;Pulmonary Fibrosis | Drug: interferon-gamma 1b;Drug: azathioprine | InterMune | NULL | Terminated | 20 Years | 79 Years | Both | 0 | Phase 3 | Italy |
| 7 | NCT00047658 (ClinicalTrials.gov) | November 2001 | 9/10/2002 | A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label Extension | Idiopathic Pulmonary Fibrosis | Drug: Interferon-gamma 1b | InterMune | NULL | Completed | 20 Years | 79 Years | Both | 32 | Phase 2 | United States |